Peggy Hours-Zesiger

799 total citations · 1 hit paper
9 papers, 540 citations indexed

About

Peggy Hours-Zesiger is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine and Physiology. According to data from OpenAlex, Peggy Hours-Zesiger has authored 9 papers receiving a total of 540 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Psychiatry and Mental health, 5 papers in Pathology and Forensic Medicine and 3 papers in Physiology. Recurrent topics in Peggy Hours-Zesiger's work include Migraine and Headache Studies (8 papers), Trigeminal Neuralgia and Treatments (5 papers) and Sympathectomy and Hyperhidrosis Treatments (3 papers). Peggy Hours-Zesiger is often cited by papers focused on Migraine and Headache Studies (8 papers), Trigeminal Neuralgia and Treatments (5 papers) and Sympathectomy and Hyperhidrosis Treatments (3 papers). Peggy Hours-Zesiger collaborates with scholars based in Switzerland, United States and Germany. Peggy Hours-Zesiger's co-authors include Shihua Wen, Jan Klatt, Uwe Reuter, Peter J. Goadsby, Michel Lantéri‐Minet, Michel D. Ferrari, Monika Maier‐Peuschel, Christian Hentschke, Astrid Gendolla and Axel Heinze and has published in prestigious journals such as The Lancet, Neurology and Journal of Neurology Neurosurgery & Psychiatry.

In The Last Decade

Peggy Hours-Zesiger

9 papers receiving 529 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study

2018 332 citations Uwe Reuter, Peter J. Goadsby et al. The Lancet profile →

Peers

Countries citing papers authored by Peggy Hours-Zesiger

Since Specialization

Citations

This map shows the geographic impact of Peggy Hours-Zesiger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peggy Hours-Zesiger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peggy Hours-Zesiger more than expected).

Fields of papers citing papers by Peggy Hours-Zesiger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peggy Hours-Zesiger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peggy Hours-Zesiger. The network helps show where Peggy Hours-Zesiger may publish in the future.

Co-authorship network of co-authors of Peggy Hours-Zesiger

This figure shows the co-authorship network connecting the top 25 collaborators of Peggy Hours-Zesiger. A scholar is included among the top collaborators of Peggy Hours-Zesiger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peggy Hours-Zesiger. Peggy Hours-Zesiger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2–4 preventives were not useful: results from the LIBERTY study 2021 ·Journal of Neurology Neurosurgery & Psychiatry ·Michel Lantéri‐Minet, Peter J. Goadsby, Uwe Reuter, Shihua Wen, Peggy Hours-Zesiger, Michel D. Ferrari, Jan Klatt	14
2	Long-term Efficacy and Safety of Erenumab 2021 ·Neurology ·Peter J. Goadsby, Uwe Reuter, Michel Lantéri‐Minet, Gabriel Paiva da Silva Lima, Peggy Hours-Zesiger, (unknown), Shihua Wen, Nadia Tenenbaum, (unknown), Michel D. Ferrari, Jan Klatt	33
3	Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study 2021 ·Cephalalgia ·Shuu‐Jiun Wang, Artemio Roxas, (unknown), (unknown), Debashish Chowdhury, Naji Riachi, Mei‐Ling Sharon Tai, Surat Tanprawate, (unknown), (unknown), Daniel D. Mikol, Shaloo Pandhi, Shihua Wen, (unknown), Nadia Tenenbaum, Peggy Hours-Zesiger	42
4	Erenumab Versus Topiramate for the Prevention of Migraine – A Randomised, Double-Blind, Active-Controlled Phase 4 Trial 2021 ·SSRN Electronic Journal ·Uwe Reuter, (unknown), Astrid Gendolla, Axel Heinze, Jan Klatt, Shihua Wen, Peggy Hours-Zesiger, (unknown), Christian Hentschke, Christian Sieder, Monika Maier‐Peuschel	13
5	Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial 2021 ·Cephalalgia ·Uwe Reuter, (unknown), Astrid Gendolla, Axel Heinze, Jan Klatt, Shihua Wen, Peggy Hours-Zesiger, (unknown), Christian Sieder, Christian Hentschke, Monika Maier‐Peuschel	93
6	Assessment of the Efficacy of Erenumab During the Open-Label Treatment (13–24 Weeks) of Subjects with Episodic Migraine Who Failed 2–4 Prior Preventive Treatments: Results of the LIBERTY Study (P1.10-002) 2019 ·Neurology ·Uwe Reuter, Peter J. Goadsby, Michel Lantéri‐Minet, Peggy Hours-Zesiger, (unknown), Michel D. Ferrari, Jan Klatt	3
7	096 Assessment of the efficacy of erenumab during the open-label treatment (13–24 weeks) of subjects with episodic migraine who failed 2–4 prior preventive treatments: results of the LIBERTY study 2019 ·Journal of Neurology Neurosurgery & Psychiatry ·Lauren Giles, Uwe Reuter, Peter J. Goadsby, Michel Lantéri‐Minet, Peggy Hours-Zesiger, (unknown), Michel D. Ferrari, Jan Klatt	2
8	Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study breakdown → 2018 ·The Lancet ·Uwe Reuter, Peter J. Goadsby, Michel Lantéri‐Minet, Shihua Wen, Peggy Hours-Zesiger, Michel D. Ferrari, Jan Klatt	332
9	Initial combination therapy with vildagliptin plus metformin in drug-naïve patients with T2DM: a 24-week real-life study from Asia 2018 ·Current Medical Research and Opinion ·Manoj Chawla, Tae Ho Kim, Roberto Mirasol, Faruque Pathan, (unknown), Peggy Hours-Zesiger, Abhijit Shete	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact